Combination stem cell therapy for heart failure

International Archives of Medicine

Volumn 3, Issue 1, 2010, Pages

  Ichim, Thomas E ^a   Solano, Fabio ^b   Lara, Fabian ^b   Rodriguez, Jorge Paz ^c   Cristea, Octav ^d   Minev, Boris ^e   Ramos, Famela ^a   Woods, Erik J ^f   Murphy, Michael P ^g   Alexandrescu, Doru T ^h   Patel, Amit N ⁱ   Riordan, Neil H ^a  

^a Medistem Inc   (United States)

^b Cell Medicine Institutes   (Costa Rica)

^c Cell Medicine Institutes   (Panama)

^d UNIVERSITY OF GUELPH   (Canada)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f General BioTechnology LLC   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Georgetown Dermatology   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 10; RECOMBINANT STROMAL CELL DERIVED FACTOR 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL DEATH; CELL HOMING; CELL MIGRATION; CELL REGENERATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONSENSUS; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG INHIBITION; ENDOMETRIAL REGENERATIVE CELL; ENDOMETRIUM CELL; HEART; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MEDIATOR; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; STEM CELL; STEM CELL NICHE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77950648738     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-3-5     Document Type: Article

References (143)

1. Inflammatory markers in stable heart failure and their relationship with functional class. IJ Sanchez-Lazaro L Almenar E Reganon V Vila L Martinez-Dolz V Martinez-Sales J Moro J Aguero V Ortiz-Martinez A Salvador, Int J Cardiol 2007 129 3 388 93 10.1016/j.ijcard.2007.07.138 18022711
2. C-reactive protein as a predictor of improvement and readmission in heart failure. JL Alonso-Martinez B Llorente-Diez M Echegaray-Agara F Olaz-Preciado M Urbieta-Echezarreta C Gonzalez-Arencibia, Eur J Heart Fail 2002 4 331 336 10.1016/S1388-9842(02)00021-1 12034159
3. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. ES Nakou EN Liberopoulos HJ Milionis MS Elisaf, Curr Vasc Pharmacol 2008 6 258 270 10.2174/157016108785909733 18855714
4. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. B Galarraga F Khan P Kumar T Pullar JJ Belch, Rheumatology (Oxford) 2008 47 12 1780 4 10.1093/rheumatology/ken386 18854346
5. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of atherosclerotic plaque. A Nabata M Kuroki H Ueba S Hashimoto T Umemoto H Wada T Yasu M Saito S Momomura M Kawakami, Atherosclerosis 2008 196 129 135 10.1016/j.atherosclerosis.2007.03.003 17531242
6. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. M Griselli J Herbert WL Hutchinson KM Taylor M Sohail T Krausz MB Pepys, J Exp Med 1999 190 1733 1740 10.1084/jem.190.12.1733 10601349
7. Targeting C-reactive protein for the treatment of cardiovascular disease. MB Pepys GM Hirschfield GA Tennent JR Gallimore MC Kahan V Bellotti PN Hawkins RM Myers MD Smith A Polara, et al. Nature 2006 440 1217 1221 10.1038/nature04672 16642000
8. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. M Satoh Y Minami Y Takahashi M Nakamura, Curr Heart Fail Rep 2008 5 69 74 10.1007/s11897-008-0012-2 18765076
9. Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. T Yokoyama K Sekiguchi T Tanaka K Tomaru M Arai T Suzuki R Nagai, Am J Physiol 1999 276 1968 1976 10362677
10. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. BW Wang HF Hung H Chang P Kuan KG Shyu, Am J Physiol Heart Circ Physiol 2007 293 2305 2312 10.1152/ajpheart. 00361.2007 17573461
11. Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. S Satoh J Oyama N Suematsu T Kadokami N Shimoyama M Okutsu T Inoue M Sugano N Makino, Int J Cardiol 2006 111 405 412 10.1016/j.ijcard.2005.08.021 16271779
12. Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. VM Conraads JM Bosmans AJ Schuerwegh I Goovaerts LS De Clerck WJ Stevens CH Bridts CJ Vrints, J Heart Lung Transplant 2005 24 854 859 10.1016/j.healun.2004.04.017 15982613
13. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. SB Haudek GE Taffet MD Schneider DL Mann, J Clin Invest 2007 117 2692 2701 10.1172/JCI29134 17694177
14. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. T Kubota GS Bounoutas M Miyagishima T Kadokami VJ Sanders C Bruton PD Robbins CF McTiernan AM Feldman, Circulation 2000 101 2518 2525 10831527
15. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. KA Scheibner MA Lutz S Boodoo MJ Fenton JD Powell MR Horton, J Immunol 2006 177 1272 1281 16818787
16. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. C Termeer F Benedix J Sleeman C Fieber U Voith T Ahrens K Miyake M Freudenberg C Galanos JC Simon, J Exp Med 2002 195 99 111 10.1084/jem.20001858 11781369
17. Heat shock proteins and toll-like receptors. A Asea, Handb Exp Pharmacol 2008 111 127 18071657
18. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. N Nozaki T Shishido Y Takeishi I Kubota, Circulation 2004 110 2869 2874 10.1161/01.CIR.0000146889.46519.27 15505089
19. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. A Riad S Bien M Gratz F Escher D Westermann MM Heimesaat S Bereswill T Krieg SB Felix HP Schultheiss, et al. Eur J Heart Fail 2008 10 233 243 10.1016/j.ejheart.2008.01.004 18321777
20. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. T Shishido N Nozaki S Yamaguchi Y Shibata J Nitobe T Miyamoto H Takahashi T Arimoto K Maeda M Yamakawa, et al. Circulation 2003 108 2905 2910 10.1161/01.CIR.0000101921.93016.1C 14656915
21. Prognostic value of activated toll-like receptor-4 in monocytes following acute myocardial infarction. JJ Sheu LT Chang CH Chiang AA Youssef CJ Wu FY Lee HK Yip, Int Heart J 2008 49 1 11 10.1536/ihj.49.1 18360060
22. Timing of adenosine 2A receptor stimulation relative to reperfusion has differential effects on infarct size and cardiac function as assessed in mice by MRI. Z Yang J Linden SS Berr IL Kron GA Beller BA French, Am J Physiol Heart Circ Physiol 2008 295 2328 2335 10.1152/ajpheart.00091.2008 18849340
23. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Z Yang YJ Day MC Toufektsian Y Xu SI Ramos MA Marshall BA French J Linden, Circulation 2006 114 2056 2064 10.1161/CIRCULATIONAHA.106.649244 17060376
24. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. AJ Friedenstein KV Petrakova AI Kurolesova GP Frolova, Transplantation 1968 6 230 247 10.1097/00007890-196803000-00009 5654088
25. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. AC Zannettino S Paton A Arthur F Khor S Itescu JM Gimble S Gronthos, J Cell Physiol 2008 214 413 421 10.1002/jcp.21210 17654479
26. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. MJ Hoogduijn MJ Crop AM Peeters GJ Van Osch AH Balk JN Ijzermans W Weimar CC Baan, Stem Cells Dev 2007 16 597 604 10.1089/scd.2006.0110 17784833
27. Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. KC Chao KF Chao YS Fu SH Liu, PLoS ONE 2008 3 1451 10.1371/journal.pone.0001451 18197261
28. Isolation and characterization of postnatal stem cells from human dental tissues. YY Jo HJ Lee SY Kook HW Choung JY Park JH Chung YH Choung ES Kim HC Yang PH Choung, Tissue Eng 2007 13 767 773 10.1089/ten.2006.0192 17432951
29. Concise review: multipotent mesenchymal stromal cells in blood. Q He C Wan G Li, Stem Cells 2007 25 69 77 10.1634/stemcells.2006-0335 16973831
30. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. W Oh DS Kim YS Yang JK Lee, Cell Immunol 2008 18495100
31. Endometrial regenerative cells: a novel stem cell population. X Meng TE Ichim J Zhong A Rogers Z Yin J Jackson H Wang W Ge V Bogin KW Chan, et al. J Transl Med 2007 5 57 10.1186/1479-5876-5-57 18005405
32. Novel Cardiac Precursor-Like Cells from Human Menstrual Blood-Derived Mesenchymal Cells. N Hida N Nishiyama S Miyoshi S Kira K Segawa T Uyama T Mori K Miyado Y Ikegami C Cui, et al. Stem Cells 2008 26 7 1695 704 10.1634/stemcells.2007-0826 18420831
33. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. AN Patel E Park M Kuzman F Benetti FJ Silva JG Allickson, Cell Transplant 2008 17 303 311 10.3727/096368908784153922 18522233
34. Immunomodulation by mesenchymal stem cells and clinical experience. K Le Blanc O Ringden, J Intern Med 2007 262 509 525 10.1111/j.1365-2796.2007.01844.x 17949362 (Pubitemid 47620502)
35. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. KA Keyser KE Beagles HP Kiem, Cell Transplant 2007 16 555 562 17708345
36. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. A Nasef A Chapel C Mazurier S Bouchet M Lopez N Mathieu L Sensebe Y Zhang NC Gorin D Thierry, et al. Gene Expr 2007 13 217 226 10.3727/000000006780666957 17605296
37. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. JM Ryan F Barry JM Murphy BP Mahon, Clin Exp Immunol 2007 149 353 363 10.1111/j.1365-2249.2007.03422.x 17521318
38. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. A Nasef C Mazurier S Bouchet S Francois A Chapel D Thierry NC Gorin L Fouillard, Cell Immunol 2008 253 16 22 10.1016/j.cellimm.2008.06.002 18639869
39. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Z Selmani A Naji I Zidi B Favier E Gaiffe L Obert C Borg P Saas P Tiberghien N Rouas-Freiss, et al. Stem Cells 2008 26 212 222 10.1634/stemcells.2007-0554 17932417
40. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. LA Ortiz M Dutreil C Fattman AC Pandey G Torres K Go DG Phinney, Proc Natl Acad Sci USA 2007 104 11002 11007 10.1073/pnas.0704421104 17569781
41. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. K English FP Barry CP Field-Corbett BP Mahon, Immunol Lett 2007 110 91 100 10.1016/j.imlet.2007.04.001 17507101
42. Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. BJ Jones G Brooke K Atkinson SJ McTaggart, Placenta 2007 28 1174 1181 10.1016/j.placenta.2007.07.001 17714779
43. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. F Casiraghi N Azzollini P Cassis B Imberti M Morigi D Cugini RA Cavinato M Todeschini S Solini A Sonzogni, et al. J Immunol 2008 181 3933 3946 18768848
44. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. I Kassis N Grigoriadis B Gowda-Kurkalli R Mizrachi-Kol T Ben-Hur S Slavin O Abramsky D Karussis, Arch Neurol 2008 65 753 761 10.1001/archneur.65.6.753 18541795
45. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. B Parekkadan AW Tilles ML Yarmush, Stem Cells 2008 26 1913 1919 10.1634/stemcells.2007-0790 18420833
46. Mesenchymal Stem Cells Alter Migratory Property of T and Dendritic Cells to Delay the Development of Murine Lethal Acute Graft-Versus-Host Disease. H Li Z Guo X Jiang H Zhu X Li N Mao, Stem Cells 2008 26 10 2531 41 10.1634/stemcells.2008-0146 18635870
47. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. A Augello R Tasso SM Negrini R Cancedda G Pennesi, Arthritis Rheum 2007 56 1175 1186 10.1002/art.22511 17393437
48. Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. P Semedo PM Wang TH Andreucci MA Cenedeze VP Teixeira MA Reis A Pacheco-Silva NO Camara, Transplant Proc 2007 39 421 423 10.1016/j.transproceed.2007.01.036 17362746
49. Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction. YY Du SH Zhou T Zhou H Su HW Pan WH Du B Liu QM Liu, Cytotherapy 2008 10 469 478 10.1080/ 14653240802129893 18608353
50. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. K Le Blanc F Frassoni L Ball F Locatelli H Roelofs I Lewis E Lanino B Sundberg ME Bernardo M Remberger, et al. Lancet 2008 371 1579 1586 10.1016/S0140-6736(08)60690-X 18468541
51. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. H Ning F Yang M Jiang L Hu K Feng J Zhang Z Yu B Li C Xu Y Li, et al. Leukemia 2008 22 593 599 10.1038/sj.leu.2405090 18185520
52. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. L Ball R Bredius A Lankester J Schweizer M van den Heuvel-Eibrink H Escher W Fibbe M Egeler, Leukemia 2008 22 1256 1257 10.1038/sj.leu.2405013 17972946
53. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. O Ringden M Uzunel I Rasmusson M Remberger B Sundberg H Lonnies HU Marschall A Dlugosz A Szakos Z Hassan, et al. Transplantation 2006 81 1390 1397 10.1097/01.tp.0000214462.63943.14 16732175
54. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. K Le Blanc I Rasmusson B Sundberg C Gotherstrom M Hassan M Uzunel O Ringden, Lancet 2004 363 1439 1441 10.1016/S0140-6736(04)16104-7 15121408
55. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. I Muller S Kordowich C Holzwarth G Isensee P Lang F Neunhoeffer M Dominici J Greil R Handgretinger, Blood Cells Mol Dis 2008 40 25 32 10.1016/j.bcmd.2007.06.021 17869550
56. Apoptosis in myocytes in end-stage heart failure. J Narula N Haider R Virmani TG DiSalvo FD Kolodgie RJ Hajjar U Schmidt MJ Semigran GW Dec BA Khaw, N Engl J Med 1996 335 1182 1189 10.1056/NEJM199610173351603 8815940
57. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. GW Dorn, Cardiovasc Res 2008 81 3 465 73 10.1093/cvr/cvn243 18779231
58. Apoptosis in myocardial infarction. M Rodriguez BR Lucchesi J Schaper, Ann Med 2002 34 470 479 10.1080/078538902321012414 12523502
59. Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. M Odashima S Usui H Takagi C Hong J Liu M Yokota J Sadoshima, Circ Res 2007 100 1344 1352 10.1161/01.RES.0000265846.23485.7a 17395874
60. Overexpression of IAP-2 attenuates apoptosis and protects against myocardial ischemia/reperfusion injury in transgenic mice. CC Chua J Gao YS Ho Y Xiong X Xu Z Chen RC Hamdy BH Chua, Biochim Biophys Acta 2007 1773 577 583 10.1016/j.bbamcr.2007.01.007 17321613
61. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. V Jayasankar YJ Woo LT Bish TJ Pirolli S Chatterjee MF Berry J Burdick TJ Gardner HL Sweeney, Circulation 2003 108 Suppl 1 I230 236 12970238
62. Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists. G Filippatos BD Uhal, Curr Pharm Des 2003 9 707 714 10.2174/1381612033455477 12570788
63. Evolution of the c-kit-positive cell response to pathological challenge in the myocardium. J Fransioli B Bailey NA Gude CT Cottage JA Muraski G Emmanuel W Wu R Alvarez M Rubio S Ottolenghi, et al. Stem Cells 2008 26 1315 1324 10.1634/stemcells.2007-0751 18308948
64. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. K Urbanek D Torella F Sheikh A De Angelis D Nurzynska F Silvestri CA Beltrami R Bussani AP Beltrami F Quaini, et al. Proceedings of the National Academy of Sciences 2005 102 8692 8697 10.1073/pnas.0500169102 (Pubitemid 40862797)
65. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. B Dawn AB Stein K Urbanek M Rota B Whang R Rastaldo D Torella XL Tang A Rezazadeh J Kajstura, et al. Proc Natl Acad Sci USA 2005 102 3766 3771 10.1073/pnas.0405957102 15734798
66. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. L Raffaghello G Bianchi M Bertolotto F Montecucco A Busca F Dallegri L Ottonello V Pistoia, Stem Cells 2008 26 151 162 10.1634/stemcells.2007-0416 17932421
67. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. M Mirotsou Z Zhang A Deb L Zhang M Gnecchi N Noiseux H Mu A Pachori V Dzau, Proc Natl Acad Sci USA 2007 104 1643 1648 10.1073/pnas.0610024104 17251350
68. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, IGF-I in response to TNF by a p38 MAPK-dependent mechanism. M Wang PR Crisostomo C Herring KK Meldrum DR Meldrum, Am J Physiol Regul Integr Comp Physiol 2006 291 880 884 16728464
69. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. K Urbanek M Rota S Cascapera C Bearzi A Nascimbene A De Angelis T Hosoda S Chimenti M Baker F Limana, et al. Circ Res 2005 97 663 673 10.1161/01.RES.0000183733.53101.11 16141414
70. Myocardial repair achieved by the intramyocardial implantation of adult cardiomyocytes in combination with bone marrow cells. TS Li M Takahashi M Ohshima SL Qin M Kubo K Muramatsu K Hamano, Cell Transplant 2008 17 695 703 10.3727/096368908786092702 18819257
71. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. PR Crisostomo Y Wang TA Markel M Wang T Lahm DR Meldrum, Am J Physiol Cell Physiol 2008 294 675 682 10.1152/ajpcell.00437.2007 18234850
72. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage. X Fu Y He C Xie W Liu, Cytotherapy 2008 10 353 363 10.1080/14653240802035926 18574768
73. Multiorgan engraftment and differentiation of human cord blood CD34+ Lin- cells in goats assessed by gene expression profiling. F Zeng MJ Chen DA Baldwin ZJ Gong JB Yan H Qian J Wang X Jiang ZR Ren D Sun, et al. Proc Natl Acad Sci USA 2006 103 7801 7806 10.1073/pnas.0602646103 16682618
74. The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. N Nishiyama S Miyoshi N Hida T Uyama K Okamoto Y Ikegami K Miyado K Segawa M Terai M Sakamoto, et al. Stem Cells 2007 25 2017 2024 10.1634/stemcells.2006-0662 17495114 (Pubitemid 47258179)
75. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. H Kawada J Fujita K Kinjo Y Matsuzaki M Tsuma H Miyatake Y Muguruma K Tsuboi Y Itabashi Y Ikeda, et al. Blood 2004 104 3581 3587 10.1182/blood-2004-04-1488 15297308
76. Plasticity and tissue regenerative potential of bone marrow-derived cells. DS Vieyra KA Jackson MA Goodell, Stem Cell Rev 2005 1 65 69 10.1385/SCR:1:1:065 17132877
77. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. S Fazel M Cimini L Chen S Li D Angoulvant P Fedak S Verma RD Weisel A Keating RK Li, J Clin Invest 2006 116 1865 1877 10.1172/JCI27019 16823487
78. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. AA Kocher MD Schuster MJ Szabolcs S Takuma D Burkhoff J Wang S Homma NM Edwards S Itescu, Nat Med 2001 7 430 436 10.1038/86498 11283669
79. [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. BE Strauer M Brehm T Zeus N Gattermann A Hernandez RV Sorg G Kogler P Wernet, Dtsch Med Wochenschr 2001 126 932 938 10.1055/s-2001-16579-1 11523014
80. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. K Hamano M Nishida K Hirata A Mikamo TS Li M Harada T Miura M Matsuzaki K Esato, Jpn Circ J 2001 65 845 847 10.1253/jcj.65.845 11548889
81. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. A Abdel-Latif R Bolli IM Tleyjeh VM Montori EC Perin CA Hornung EK Zuba-Surma M Al-Mallah B Dawn, Arch Intern Med 2007 167 989 997 10.1001/archinte.167.10.989 17533201
82. Stem cell treatment for acute myocardial infarction. E Martin-Rendon S Brunskill C Doree C Hyde S Watt A Mathur S Stanworth, Cochrane Database Syst Rev 2008 D006536 18843721
83. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. S Kang YJ Yang CJ Li RL Gao, Coron Artery Dis 2008 19 327 335 10.1097/MCA.0b013e328300dbd3 18607170
84. Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: A meta-analysis of randomised controlled trials. SN Zhang AJ Sun JB Ge K Yao ZY Huang KQ Wang YZ Zou, Int J Cardiol 2009 136 2 178 85 10.1016/j.ijcard.2008.04.071 18644638
85. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. MB Herrera B Bussolati S Bruno L Morando G Mauriello-Romanazzi F Sanavio I Stamenkovic L Biancone G Camussi, Kidney Int 2007 72 430 441 10.1038/sj.ki.5002334 17507906
86. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. R Sackstein JS Merzaban DW Cain NM Dagia JA Spencer CP Lin R Wohlgemuth, Nat Med 2008 14 181 187 10.1038/nm1703 18193058
87. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. H Zhu N Mitsuhashi A Klein LW Barsky K Weinberg ML Barr A Demetriou GD Wu, Stem Cells 2006 24 928 935 10.1634/stemcells.2005-0186 16306150
88. SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Y Wang Y Deng GQ Zhou, Brain Res 2008 1195 104 112 10.1016/j.brainres.2007.11.068 18206136
89. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Z Cheng L Ou X Zhou F Li X Jia Y Zhang X Liu Y Li CA Ward LG Melo, et al. Mol Ther 2008 16 571 579 10.1038/sj.mt.6300374 18253156
90. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. A Neschadim JA McCart A Keating JA Medin, Biol Blood Marrow Transplant 2007 13 1407 1416 10.1016/j.bbmt.2007.09.014 18022569
91. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. SC Hung RR Pochampally SC Hsu C Sanchez SC Chen J Spees DJ Prockop, PLoS ONE 2007 2 416 10.1371/journal.pone.0000416 17476338
92. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. M Shi J Li L Liao B Chen B Li L Chen H Jia RC Zhao, Haematologica 2007 92 897 904 10.3324/haematol.10669 17606439
93. Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1alpha (SDF-1alpha) treatment. YL Tang K Qian YC Zhang L Shen MI Phillips, Regul Pept 2005 125 1 8 10.1016/j.regpep.2004. 10.014 15582707
94. Fibrin glue: the perfect operative sealant? JW Gibble PM Ness, Transfusion 1990 30 741 747 10.1046/j.1537-2995.1990.30891020337.x 2219264
95. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. G Zhang Y Nakamura X Wang Q Hu LJ Suggs J Zhang, Tissue Eng 2007 13 2063 2071 10.1089/ten.2006.0013 17518719
96. Endogenous cardiac stem cells. L Barile E Messina A Giacomello E Marban, Prog Cardiovasc Dis 2007 50 31 48 10.1016/j.pcad.2007.03.005 17631436
97. Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor. Y Tan H Shao D Eton Z Yang L Alonso-Diaz H Zhang A Schulick AS Livingstone H Yu, Cardiovasc Res 2007 73 823 832 10.1016/j.cardiores.2006.12.015 17258698
98. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? R Latini M Brines F Fiordaliso, Heart Fail Rev 2008 13 415 423 10.1007/s10741-008-9084-z 18236153
99. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. S Brunner J Winogradow BC Huber MM Zaruba R Fischer R David G Assmann N Herbach R Wanke J Mueller-Hoecker, et al. FASEB J 2008 23 2 351 61 10.1096/fj.08-109462 18827024
100. Circulating endothelial progenitor cells: a new approach to anti-aging medicine? NA Mikirova JA Jackson R Hunninghake J Kenyon KW Chan CA Swindlehurst B Minev AN Patel MP Murphy L Smith, et al. J Transl Med 2009 7 106 10.1186/1479-5876-7-106 20003528
101. Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly selected small patient cohort. J Babin-Ebell HH Sievers EI Charitos HM Klein F Jung AK Hellberg R Depping HA Sier J Marxsen S Stoelting, et al. Thorac Cardiovasc Surg 58 11 16 10.1055/s-0029-1186199 20072970
102. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. SM Chambers CA Shaw C Gatza CJ Fisk LA Donehower MA Goodell, PLoS Biol 2007 5 201 10.1371/journal.pbio.0050201 17676974
103. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. C Schmidt-Lucke L Rossig S Fichtlscherer M Vasa M Britten U Kamper S Dimmeler AM Zeiher, Circulation 2005 111 2981 2987 10.1161/CIRCULATIONAHA.104.504340 15927972
104. Little evidence for developmental plasticity of adult hematopoietic stem cells. AJ Wagers RI Sherwood JL Christensen IL Weissman, Science 2002 297 2256 2259 10.1126/science.1074807 12215650
105. Bone Marrow-Derived Mesenchymal Stromal Cells Express Cardiac-Specific Markers, Retain the Stromal Phenotype and do not Become Functional Cardiomyocytes In Vitro. RA Rose H Jiang X Wang S Helke JN Tsoporis N Gong SC Keating TG Parker PH Backx A Keating, Stem Cells 2008 26 11 2884 92 10.1634/stemcells.2008-0329 18687994
106. Cardiomyocytes can be generated from marrow stromal cells in vitro. S Makino K Fukuda S Miyoshi F Konishi H Kodama J Pan M Sano T Takahashi S Hori H Abe, et al. J Clin Invest 1999 103 697 705 10.1172/JCI5298 10074487
107. Autologous transplantation of bone marrow cells improves damaged heart function. S Tomita RK Li RD Weisel DA Mickle EJ Kim T Sakai ZQ Jia, Circulation 1999 100 I247 256 10567312
108. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. L De Felice C Tatarelli MG Mascolo C Gregorj F Agostini R Fiorini V Gelmetti S Pascale F Padula MT Petrucci, et al. Cancer Res 2005 65 1505 1513 10.1158/0008-5472.CAN-04-3063 15735039
109. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. G Bug H Gul K Schwarz H Pfeifer M Kampfmann X Zheng T Beissert S Boehrer D Hoelzer OG Ottmann, et al. Cancer Res 2005 65 2537 2541 10.1158/0008-5472.CAN-04-3011 15805245
110. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. TM Lee MS Lin NC Chang, Am J Physiol Heart Circ Physiol 2007 293 968 977 10.1152/ajpheart.00891.2006 17400721
111. Epigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells. N Hattori Y Imao K Nishino J Ohgane S Yagi S Tanaka K Shiota, Genes Cells 2007 12 387 396 10.1111/j.1365-2443.2007.01058.x 17352742
112. Forced expression of Sox2 or Nanog in human bone marrow derived mesenchymal stem cells maintains their expansion and differentiation capabilities. MJ Go C Takenaka H Ohgushi, Exp Cell Res 2008 314 1147 1154 10.1016/j.yexcr.2007.11.021 18187129
113. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. K Takahashi S Yamanaka, Cell 2006 126 663 676 10.1016/j.cell.2006.07.024 16904174
114. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. K Takahashi K Tanabe M Ohnuki M Narita T Ichisaka K Tomoda S Yamanaka, Cell 2007 131 861 872 10.1016/j.cell.2007.11.019 18035408
115. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. J Hanna M Wernig S Markoulaki CW Sun A Meissner JP Cassady C Beard T Brambrink LC Wu TM Townes, et al. Science 2007 318 1920 1923 10.1126/science.1152092 18063756
116. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. JB Kim H Zaehres G Wu L Gentile K Ko V Sebastiano MJ Arauzo-Bravo D Ruau DW Han M Zenke, et al. Nature 2008 454 646 650 10.1038/nature07061 18594515
117. Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors. K Okita M Nakagawa H Hyenjong T Ichisaka S Yamanaka, Science 2008 322 5903 949 53 10.1126/science.1164270 18845712
118. Tumor progression of culture-adapted human embryonic stem cells during long-term culture. S Yang G Lin YQ Tan D Zhou LY Deng DH Cheng SW Luo TC Liu XY Zhou Z Sun, et al. Genes Chromosomes Cancer 2008 47 665 679 10.1002/gcc.20574 18470900
119. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. I Ben-Porath MW Thomson VJ Carey R Ge GW Bell A Regev RA Weinberg, Nat Genet 2008 40 499 507 10.1038/ng.127 18443585
120. Human embryonic stem cells possess immune-privileged properties. L Li ML Baroja A Majumdar K Chadwick A Rouleau L Gallacher I Ferber J Lebkowski T Martin J Madrenas, et al. Stem Cells 2004 22 448 456 10.1634/stemcells.22-4-448 15277692
121. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. S Slavin BG Kurkalli D Karussis, Clin Neurol Neurosurg 2008 110 9 943 6 10.1016/j.clineuro.2008.01.014 18325660
122. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. M von Bonin F Stolzel A Goedecke K Richter N Wuschek K Holig U Platzbecker T Illmer M Schaich J Schetelig, et al. Bone Marrow Transplant 2008 43 3 245 51 10.1038/bmt.2008.316 18820709
123. Neurological and functional recovery in human stroke are associated with peripheral blood CD34+ cell mobilization. A Dunac C Frelin M Popolo-Blondeau M Chatel MH Mahagne PJ Philip, J Neurol 2007 254 327 332 10.1007/s00415-006-0362-1 17345048
124. Circulating CD34-positive cells have prognostic value for neurologic function in patients with past cerebral infarction. A Taguchi N Nakagomi T Matsuyama A Kikuchi-Taura H Yoshikawa Y Kasahara H Hirose H Moriwaki T Nakagomi T Soma, et al. J Cereb Blood Flow Metab 2008 29 1 34 8 10.1038/jcbfm.2008.92 18698330
125. Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction. F Grundmann C Scheid D Braun C Zobel H Reuter RH Schwinger J Muller-Ehmsen, Clin Res Cardiol 2007 96 621 627 10.1007/s00392-007-0543-7 17676354
126. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. MB Herrera B Bussolati S Bruno V Fonsato GM Romanazzi G Camussi, Int J Mol Med 2004 14 1035 1041 15547670
127. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. C Seebach D Henrich R Tewksbury K Wilhelm I Marzi, Calcif Tissue Int 2007 80 294 300 10.1007/s00223-007-9020-6 17431529
128. Direct visualization of neo-vessel formation following peripheral injection of bone marrow derived CD34+ cells in experimental myocardial damage. MM Ciulla S Ferrero U Gianelli R Paliotti F Magrini P Braidotti, Micron 2007 38 321 322 10.1016/j.micron.2006.08.007 17097882
129. Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. W Wojakowski M Tendera, Folia Histochem Cytobiol 2005 43 229 232 16382890
130. Human hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. E Paczkowska B Larysz R Rzeuski A Karbicka R Jalowinski Z Kornacewicz-Jach MZ Ratajczak B Machalinski, Eur J Haematol 2005 75 461 467 10.1111/j.1600-0609.2005.00536.x 16313257
131. Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. XY Wang Y Lan WY He L Zhang HY Yao CM Hou Y Tong YL Liu G Yang XD Liu, et al. Blood 2008 111 2436 2443 10.1182/blood-2007-07-099333 18045971
132. Stromal cell associated haemopoiesis. TM Dexter, J Cell Physiol Suppl 1982 1 87 94 10.1002/jcp.1041130414 7040421
133. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. T Bakhshi RC Zabriskie S Bodie S Kidd S Ramin LA Paganessi SA Gregory HC Fung KW Christopherson, Transfusion 2008 48 12 2638 44 10.1111/j.1537-2995.2008.01926.x 18798803
134. Ex vivo expansion and transplantation of hematopoietic stem/progenitor cells supported by mesenchymal stem cells from human umbilical cord blood. GP Huang ZJ Pan BB Jia Q Zheng CG Xie JH Gu IK McNiece JF Wang, Cell Transplant 2007 16 579 585 10.3727/096368907783338181 17912949
135. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. VS Urban J Kiss J Kovacs E Gocza V Vas E Monostori F Uher, Stem Cells 2008 26 244 253 10.1634/stemcells.2007-0267 17932424
136. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. TE Ichim F Solano R Brenes E Glenn J Chang K Chan NH Riordan, Reprod Biomed Online 2008 16 898 905 18549704
137. Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? MP Murphy H Wang AN Patel S Kambhampati N Angle K Chan AM Marleau A Pyszniak E Carrier TE Ichim, et al. J Transl Med 2008 6 45 10.1186/1479-5876-6-45 18713449
138. Myogenic transdifferentiation of menstrual blood-derived cells. M Toyoda C Cui A Umezawa, Acta Myol 2007 26 176 178 18646568
139. Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. CH Cui T Uyama K Miyado M Terai S Kyo T Kiyono A Umezawa, Mol Biol Cell 2007 18 1586 1594 10.1091/mbc.E06-09-0872 17314403
140. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. N Hida N Nishiyama S Miyoshi S Kira K Segawa T Uyama T Mori K Miyado Y Ikegami C Cui, et al. Stem Cells 2008 26 1695 1704 10.1634/stemcells.2007-0826 18420831
141. Inhibition of intracranial glioma growth by endometrial regenerative cells. X Han X Meng Z Yin A Rogers J Zhong P Rillema JA Jackson TE Ichim B Minev E Carrier, et al. Cell Cycle 2009 8 606 610 19197154
142. Menstrual blood stromal cells: the potential for regenerative medicine. AN Patel F Silva, Regen Med 2008 3 443 444 10.2217/17460751.3.4.443 18588464
143. Feasibility investigation of allogeneic endometrial regenerative cells. Z Zhong AN Patel TE Ichim NH Riordan H Wang WP Min EJ Woods M Reid E Mansilla GH Marin, et al. J Transl Med 2009 7 15 10.1186/1479-5876-7-15 19232091